cendoc bogani publicaciones PMD conductas adictivas

Ficha Bibliografía científica

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study)

Barre, Tangui; Marcellin, Fabienne; Di Beo, Vincent; Delorme, Jessica; Rojas, Teresa Rojas; Mathurin, Philippe; Protopopescu, Camelia; Bailly, Francois; Coste, Marion; Authier, Nicolas; Carrieri, Maria Patrizia; Rolland, Benjamin

Año: 2020

Background and Aims Although people who inject drugs (PWID) are the core at-risk population in the hepatitis C virus (HCV) epidemic in industrialized countries, few initiate treatment. Alcohol use disorder (AUD), common within this population, has been identified as a barrier to HCV treatment uptake in the general population. We investigated whether the arrival of new and well-tolerated HCV treatments (direct-acting antivirals: DAA) has improved HCV treatment uptake in French PWID compared with former treatments (pegylated interferon-based treatments: Peg-IFN). Design Using discrete-time Cox proportional hazards models based on exhaustive care delivery data, we tested for associations between AUD (defined by AUD-related long-term illness status, diagnosis coding during hospitalization and/or AUD pharmacological treatment) and first HCV treatment delivery, after adjusting for gender, age, complementary universal health cover, liver disease severity and type of opioid agonist therapy (OAT) received. Separate analyses were performed for 2012-13 (Peg-IFN era) and 2014-16 (DAA era). Setting France. Participants All French people chronically HCV-infected who received OAT at least once during 2012-16 and were covered by the national health insurance (n = 24 831). Measurements Incidence rate of HCV treatment uptake, hazard ratios associated with AUD and other covariates. Findings Incidence rate (IR) of HCV treatment uptake per 100 person-years was 6.56, confidence interval (CI) = 6.30-6.84; and IR = 5.70, 95% CI = 5.51-5.89 for Peg-IFN-based treatment (2012-13) and DAA (2014-16), respectively. After multiple adjustment, people with AUD not receiving related medication had 30 and 14% lower Peg-IFN-based treatment and DAA uptake, respectively, than those without AUD [hazard ratio (HR) = 0.70, 95% CI = 0.62-0.80 and HR = 0.86, 95% CI = 0.78-0.94]. No difference was observed between those treated for AUD and those without AUD. Conclusions Despite the benefits of direct-acting antiviral treatment, untreated alcohol use disorder appears to remain a major barrier to hepatitis C virus treatment access for people who inject drugs in France.

Tipo documento:

Artículo

Número/Volumen:

115

Páginas:

573 - 582

Fuente:

ADDICTION

Palabras clave:

Alcohol use disorder; AUD treatment; direct-acting antivirals; France; hepatitis C virus treatment; people who inject drugs

 

Comparte con otras personas

Compartir Compartir  Compartir

Regidoría de Salut i Consum del Ajuntament de València

Logotipo Universitat de València
Logotipo UISYS
Logotipo CSIC
Logotipo Consellería de Sanitat Universal y Salut Pública de la Generalitat Valenciana

Siguenos en:

 

Última actualización: 26/10/2020

Centro de documentación sobre drogodependencias y otros trastornos adictivos Dr. Emilio Bogani Miquel
Cendoc Bogani

Publicaciones, Artículos, Carteles, Posters y enlaces Web sobre Drogodependencias y Trastornos Adictivos relevantes para profesionales de las Ciencias de la Salud, Educación e Información.

Copyright © Centro de documentación sobre drogodependencias y otros trastornos adictivos Dr. Emilio Bogani Miquel, 2019.
Cendoc Bogani - C/ Amadeo de Saboya, 11 - bajo - 46010 - Valencia
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y con fines estadísticos. Al continuar con la navegación entendemos que se acepta nuestra política de cookies. Más Información